中国科技核心期刊
CN:31-1600/Q
ISSN:1004-0374
“健康与疾病的免疫”国际学术研讨会通知      关于有网站冒充本刊网站的声明
《生命科学》 2016, 28(4): 475-479
PD-1/PD-L1抗体在肿瘤临床治疗中的应用
魏木兰,王艳林,秦 烨*
(三峡大学医学院肿瘤微环境与免疫治疗湖北省重点实验室,宜昌 443002)
摘 要:PD-1 是主要表达在活化T 细胞上的免疫抑制性受体,与表达在肿瘤细胞表面的配体PD-L1 结合,通过降低T 细胞的免疫应答,使肿瘤免疫逃逸。靶向PD-1/PD-L1 这一信号通路的单克隆抗体类药物的研发是当前抗肿瘤治疗领域的研究热点。目前,已有多项临床研究提示,PD-1 及PD-L1 抗体药物治疗肿瘤的疗效显著且不良反应较小,有望改善部分晚期肿瘤患者的预后。
 
PD-1 and PD-L1 antibody in clinical cancer therapy
WEI Mu-Lan, WANG Yan-Lin, QIN Ye*
(Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Medical College, Three Gorges University, Yichang 443002, China)
Abstract: Programmed cell death-1(PD-1) is an immuno-inhibitory receptor mainly expressed in actived T cells. When binding to its ligand PD-L1 which is expressed on the surface of tumor cells, PD-1 could transduce a signal that inhibits T cell-mediated immune response and contributes to tumor immune evasion. Recently, the development of monoclonal antibodies targeting the pathway of PD-1/PD-L1 is the focus of antitumor treatment. And many clinical trials have shown that PD-1/PD-L1 antibodies have profound effects on antitumor treatment with low toxicity, expecting to improve the prognosis of patients with advanced tumors.
 
首页 | 刊物简介 | 编委会 | 投稿须知 | 广告业务 | 过刊浏览 | 联系我们
中国科学院上海生命科学信息中心《生命科学》编辑部
Copyright © 2012-2015 《生命科学》编辑部 All Rights Reserved.
沪ICP备05033115号-30
您是第3069984 位访问者,欢迎!